2026 Interim Report
Filed with HKEX · Stock code 6086 · · 55 pages · English
2 Definitions and Glossary of Technical Terms 6 Corporate Information 8 Key Highlights 10 Management Discussion and Analysis 25 Corporate Governance and Other Information 36 Report on Review of Condensed Consolidated Financial Statements 37 Consolidated Statement of Profit or Loss and Other Comprehensive Income 38 Consolidated Statement of Financial Position 40 Consolidated Statement of Changes in
Earlier from Fangzhou
- Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum
- Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
- Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability
- Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
- Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services
Later from Fangzhou
- Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner
- Adoption of share incentive scheme
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Fangzhou into a list and get an email when it puts out news.
Follow Fangzhou